Biographies
Team Members

Elizabeth (Lisa) Henske
Director of the Center for LAM Research and Clinical Care

Elizabeth (Lisa) Petri Henske is the Director of the Center for LAM Research and Clinical Care at Brigham and Women’s Hospital, Professor of Medicine at Harvard Medical School, and a practicing medical oncologist at the Dana-Farber Cancer Institute.  LAM (lymphangioleiomyomatosis) is a destructive lung disease of women leading to lung collapse and respiratory failure, often with rapid progression during pregnancy.   Dr. Henske provides clinical care for women with LAM (both TSC-associated and sporadic LAM) and for individuals with TSC-associated and sporadic angiomyolipomas.  Dr. Henske’s laboratory made the pivotal discovery that sporadic LAM is caused by bi-allelic somatic mutations in the tuberous sclerosis complex 2 (TSC2) gene, leading to clinical trials demonstrating efficacy of mTORC1 inhibitors.  Her research laboratory is focused on the cellular, metabolic, and immunologic mechanisms underlying the pathogenesis of tuberous sclerosis complex (TSC) and LAM.  She is a member of the American Society for Clinical Investigation and has received awards for her research from the Tuberous Sclerosis Alliance, The LAM Foundation, the American Thoracic Society, and the Society for Women’s Health Research.  She is a past member of the Board of Directors of The LAM Foundation and a current member of the Board of the TSC Alliance.